Featured Research

from universities, journals, and other organizations

Researchers Unveil Vital Key To Cancer

Date:
August 7, 2008
Source:
University of Manchester
Summary:
University of Manchester scientists have uncovered the 3-D structure of Mps1 -- a protein that regulates the number of chromosomes during cell division and thus has an essential role in the prevention of cancer -- which will lead to the design of safer and more effective therapies.

Crystalline structure of Mps1.
Credit: Image courtesy of University of Manchester

University of Manchester scientists have uncovered the 3D structure of Mps1 – a protein that regulates the number of chromosomes during cell division and thus has an essential role in the prevention of cancer – which will lead to the design of safer and more effective therapies.

Mps1 belongs to the family of proteins called kinases. When subsets of these enzymes become deregulated, cancer can be one of the outcomes – making them a critical target for research by oncologists. Over 100 of the 500 or so kinases have been shown to be associated with cancer, but so far scientists only know the 3D structure of a handful. Knowing the structure is critical for the design of new kinase inhibitors as therapeutic agents, an area of enormous importance to the pharmaceutical industry. Over 100 kinase inhibitors are currently in clinical trials, and the revolutionary kinase inhibitor Glivec was approved for treating Leukaemia in the UK in 2001.

Mps1 is particularly important as it controls a ‘checkpoint’ that cells use to encourage accurate chromosome sorting during mitosis. Mps1 therefore prevents aneuploidy, the change in the number of chromosomes that is closely associated with cancer.

Dr Patrick Eyers and his team, including Hong Kong-born PhD student Matthew Chu, used the Diamond Light synchrotron, a “super-microscope” that works by speeding electrons around a huge doughnut-shaped chamber the size of five football pitches until they are travelling so fast they emit high energy particles. The X-rays were “fired” at a pure sample of the protein, allowing the researchers to “see” the protein’s atomic structure for the first time.

Their structure revealed the pocket where Mps1 binds to ATP, the natural substrate from which Mps1 transfers a phosphate group to its cellular target proteins. Further work showed the protein in complex with the ATP-competitive inhibitor SP600125, a well-known but non-specific inhibitor of many kinases, which revealed a secondary pocket not utilised by this compound. If a next-generation drug can be designed to specifically block this secondary pocket, it is hoped that Mps1 will be specifically disabled, killing rapidly dividing cells such as those found in tumours.

The team hopes its work will allow chemists to design an anti-cancer drug with fewer side effects, allowing scientists to assess the relative importance of Mps1 inhibition in different disease indications, including those that are currently hard to treat such as lung and pancreatic cancers.

Dr Eyers, whose findings are published in the Journal of Biological Chemistry (August 2008), said: “The crystallalographic structures of only a few key “mitotic” kinases are currently known so we are very early in the game. The scientific community has high hopes for developing novel “anti-mitotic” cancer therapies using this method of structure-based drug design.

“Mps1 is a rational target because of its critical role in preventing aneuploidy. We wanted to see what this protein looked like at the molecular level and, by revealing the active site “lock”, help design a new inhibitory “key” to physically block the ATP-binding site.

His colleague Dr Lydia Tabernero added: “This work presents the first crystallographic structure of human Mps1, an important regulator of chromosomal stability and a potential target in cancer therapy. Our research has revealed several important structural features and additional binding sites that could be exploited for the development of specific Mps1 inhibitors.”


Story Source:

The above story is based on materials provided by University of Manchester. Note: Materials may be edited for content and length.


Cite This Page:

University of Manchester. "Researchers Unveil Vital Key To Cancer." ScienceDaily. ScienceDaily, 7 August 2008. <www.sciencedaily.com/releases/2008/08/080806113151.htm>.
University of Manchester. (2008, August 7). Researchers Unveil Vital Key To Cancer. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2008/08/080806113151.htm
University of Manchester. "Researchers Unveil Vital Key To Cancer." ScienceDaily. www.sciencedaily.com/releases/2008/08/080806113151.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins